These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17967909)

  • 1. Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.
    Buckheit RW; Hartman TL; Watson KM; Chung SG; Cho EH
    Antimicrob Agents Chemother; 2008 Jan; 52(1):225-36. PubMed ID: 17967909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.
    Buckheit RW; Watson K; Fliakas-Boltz V; Russell J; Loftus TL; Osterling MC; Turpin JA; Pallansch LA; White EL; Lee JW; Lee SH; Oh JW; Kwon HS; Chung SG; Cho EH
    Antimicrob Agents Chemother; 2001 Feb; 45(2):393-400. PubMed ID: 11158731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.
    Buckheit RW; Hartman TL; Watson KM; Kwon HS; Lee SH; Lee JW; Kang DW; Chung SG; Cho EH
    Antivir Chem Chemother; 2007; 18(5):259-75. PubMed ID: 18046959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
    Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410.
    Buckheit RW; Watson Buckheit K; Sturdevant CB; Buckheit RW
    Antiviral Res; 2013 Nov; 100(2):382-91. PubMed ID: 24055450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents.
    Hartman TL; Yang L; Buckheit RW
    Antiviral Res; 2011 Dec; 92(3):505-8. PubMed ID: 22036651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors.
    Huang Y; Wang X; Yu X; Yuan L; Guo Y; Xu W; Liu T; Liu J; Shao Y; Ma L
    Virol J; 2011 May; 8():230. PubMed ID: 21569631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative structure-activity relationship studies on some anti-human-immunodeficiency-virus-1 (anti-HIV-1) drugs: viral reverse transcriptase inhibitors.
    Garg R; Gupta SP
    J Enzyme Inhib; 1997 Apr; 12(1):1-12. PubMed ID: 9204378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
    Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
    AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.
    He Y; Chen F; Yu X; Wang Y; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Chem; 2004 Dec; 32(6):536-48. PubMed ID: 15530994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
    Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
    Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
    Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Zhang J; Zhan P; Wu J; Li Z; Jiang Y; Ge W; Pannecouque C; De Clercq E; Liu X
    Bioorg Med Chem; 2011 Jul; 19(14):4366-76. PubMed ID: 21683601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Chen W; Zhan P; Rai D; De Clercq E; Pannecouque C; Balzarini J; Zhou Z; Liu H; Liu X
    Bioorg Med Chem; 2014 Mar; 22(6):1863-72. PubMed ID: 24581546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.
    Dollé V; Fan E; Nguyen CH; Aubertin AM; Kirn A; Andreola ML; Jamieson G; Tarrago-Litvak L; Bisagni E
    J Med Chem; 1995 Nov; 38(23):4679-86. PubMed ID: 7473595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
    Tabassum T; Azeem SM; Muwonge AN; Frey KM
    Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
    Miller V; de Béthune MP; Kober A; Stürmer M; Hertogs K; Pauwels R; Stoffels P; Staszewski S
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3123-9. PubMed ID: 9835502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.